Posts Tagged ‘ retinal vein occlusion ’
NICE Consults On Dexamethasone Intravitreal Implant For The Treatment Of Macular Oedema Secondary To Retinal Vein Occlusion
In preliminary recommendations published today (8 February) NICE is asking Allergan for more information on its product dexamethasone (Ozurdex) intravitreal implant, for the treatment of macular oedema secondary to retinal vein occlusion (RVO). The m...
Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in CRVO and in Phase 2 Study in DME
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the COPERNICUS study, which is led by Regeneron, the first of two Phase 3 studies in patients with m...
Interim guidance for management of retinal vein occlusion 2010
The document aims to provide updated recommendations on the management of retinal vein occlusion (RVO) in the light of recent developments in both diagnostic tools and treatment options that supersede those in the previous RVO guidelines. It has also reviewed the risk factors for RVOs and included recommendations for investigations and indications for medical management.
Cochrane Review Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion
Central retinal vein occlusion (CRVO) is a common retinal vascular disorder in which macular edema (ME) may develop, with a consequent reduction in visual acuity. The visual prognosis in CRVO-ME is poor in a substantial proportion of patients, especially those with the ischemic subtype, and until recently there has been no treatment of proven benefit. Macular grid laser treatment is ineffective, and whilst a few recent randomized controlled trials (RCTs) suggest short-term gains in visual acuity with intravitreal steroids for patients with non-ischemic CRVO-ME, there is no established treatment for ischemic CRVO-ME. Anti-vascular endothelial growth factor (anti-VEGF) agents have been used to treat ME resulting from a variety of causes and may represent a treatment option for CRVO-ME.
Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE 2)
Status: Recruiting,
Condition Summary: Ischemia; Retinal Vein Occlusion; Pathologic Processes; Retinal Diseases; Eye Diseases
Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion
New Cochrane review issued on 6th October 2010.
BRAVO and CRUISE: 12-Month Outcomes Revealed
In this video commentary, Dr. David Brown reports on the 12-month outcomes of the BRAVO and CRUISE studies presented at ARVO 2010. What is the impact on retinal vein occlusion treatment?
How Should We Treat Retinal Vein Occlusion?
Drs. David Brown, Ingrid Scott, and Peter Campochiaro discuss pivotal data recently presented on the treatment of BRVO and CRVO.
Subscribe
